Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cecile A. Mather"'
Autor:
Joachim von Pawel, Luis Paz-Ares, Ian Taylor, Hui Zhang, Pasi A. Jänne, Jaafar Bennouna, Zelanna Goldberg, Lara Carmen Iglesias Docampo, Jim P. Doherty, Cecile B. Mather, Mikhail Shtivelband, Tony Mok, Jane Q. Liang, Kenneth J. O'Byrne, Suresh S. Ramalingam, Joe O'Connell, Adam Pluzanski, Michael Boyer
Publikováno v:
The Lancet Oncology. 15:1369-1378
Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. We aimed to compare dacomitinib with erlotinib i
Autor:
Abraham Chachoua, Cecile B. Mather, Luiz E Raez, Chandra P. Belani, Rebecca J. Benner, Peter D Eisenberg, John Nemunaitis, J Daniel Cuevas, Sandra J. Meech
Publikováno v:
Cancer Biology & Therapy. 14:557-563
This phase 2 study assessed PF-3512676 plus erlotinib in patients with epidermal growth factor receptor-positive advanced non-small cell lung cancer after prior chemotherapy failure. Patients were randomized 1:1 to PF-3512676 (0.20 mg/kg injected sub
Autor:
Luis Paz-Ares, Kenneth J. O'Byrne, Hui Zhang, S.S. Ramalingam, Pasi A. Jänne, Zelanna Goldberg, Ian Taylor, Cecile B. Mather, Michael Boyer, Tony Mok
Publikováno v:
Annals of Oncology. 26:i29
Autor:
Ian Taylor, Joe O'Connell, Pasi A. Jänne, Jiin Ahn, Michael Boyer, Luis Paz-Ares, Cecile B. Mather, Hui Zhang, S.S. Ramalingam, Tony Mok, Kenneth J. O'Byrne
Publikováno v:
Annals of Oncology. 25:iv435
Aim: Dacomitinib is an irreversible pan-HER kinase inhibitor with activity in advanced NSCLC. In a Phase 2 trial in pt previously treated with chemotherapy, D showed improved PFS compared to E (median PFS 12 .4 weeks vs. 8.3 weeks; HR 0.66, P = 0.012
Autor:
Luis Paz-Ares, Jane Q. Liang, Suresh S. Ramalingam, Cecile A. Mather, Ian Taylor, Hui Zhang, Michael Boyer, Jim P. Doherty, Tony Mok, Kenneth J. O'Byrne, Joe O'Connell, Pasi A. Jänne
Publikováno v:
Journal of Clinical Oncology. 32:8018-8018
8018 Background: Dacomitinib, an irreversible pan-HER kinase inhibitor, has demonstrated anti-cancer activity in phase 2 studies for patients with EGFR activating mutation and in those with EGFR an...